MPM BioImpact’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

MPM BioImpact’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,173,809	Closed	-$28.3M	–	40
2023 Q1	$28.3M	Buy	1,173,809 +275,326	+31%	+$3.46M	7.35%	2
2022 Q4	$9.5M	Buy	898,483 +158,139	+21%	+$1.28M	2.46%	12
2022 Q3	$3.33M	Buy	740,344 +147,909	+25%	+$674K	0.79%	24
2022 Q2	$2.37M	Buy	+592,435	New	+$2.81M	0.66%	31

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

MPM BioImpact's PRVB Position: Q2 2023 in Review

MPM BioImpact sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 1,173,809 shares — an estimated $28.3M sold.

MPM BioImpact first reported a position in PRVB in Q2 2022 and held it in 4 quarters. The position peaked at $28.3M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

MPM BioImpact reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
MPM BioImpact sold 1,173,809 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $28.3M.
MPM BioImpact first reported a position in Provention Bio, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
MPM BioImpact's Provention Bio, Inc. Common Stock position peaked at $28.3M in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on MPM BioImpact's 13F filing for Q2 2023, filed 14 Aug 2023.